Allergic rhinoconjunctivitis: Burden of disease
Allergic rhinoconjunctivitis: Burden of disease
复制标题
DOI：
10.2500/aap.2007.28.3013
复制
发表时间：
2007-07-01
影响因子：
2.8
通讯作者：
Blaiss, Michael S.
中科院分区：
文献类型：
--
作者：
Blaiss, Michael S.
尽管没有与过敏性鼻结膜炎（AR）相关的死亡率，但这种疾病的患者中有显著的发病率。AR患者的确切数量难以确定，研究显示范围为9%至42%的人群。最近，美国过敏症调查发现，14.2%的美国成年人被诊断患有AR。众所周知，AR对患者的生活质量有着深远的影响。AR患者不仅抱怨流涕、鼻塞、打喷嚏、瘙痒和相关的眼部问题，而且他们的情绪健康和社会功能也受到损害。成本是AR研究的主要负担，每年至少有60亿美元。虽然大多数关注与成本相关的AR一直在评估由于医生咨询和医疗的直接成本，但现在很明显，间接成本是AR总成本的一个主要方面，特别是对美国企业来说。间接成本包括因病缺勤或缺课，以及工作时生产力下降或出勤。医学界应认真对待AR。对AR患者的适当治疗不仅可以大大改善他们的生活质量，还可以降低与这种疾病相关的医疗费用，特别是间接费用。
Even though there is no mortality associated with allergic rhinoconjunctivitis (AR), there is significant morbidity in sufferers of this condition. The exact number of patients with AR is difficult to ascertain, with studies showing ranges from 9 to 42% of the population. Recently, the Allergies in America survey found that 14.2% of the adult U.S. population has been diagnosed with AR. It is well established that AR has a profound influence on the patient's quality of life. Not only do people with AR complain of rhinorrhea, nasal congestion, sneezing, itching, and associated eye problems disturbing, but they also have impaired emotional wellbeing and social functioning. Costs are a major burden in AR studies showing at least $6 billionlyear. Although most attention related to costs in AR have been evaluating direct costs due to physician consultation anti medical treatment, it is now clear that indirect costs are a major aspect of total costs in AR, especially for American businesses. Indirect costs include absenteeism from work or school because of illness and decreased productivity when at work or presenteeism. AR should be treated seriously by the medical community. Proper treatment of AR patients should not only greatly improve their quality of life, but also bring down health care costs, especially indirect ones, associated with this condition.